top of page
lab_beaker.jpg

Innovative Research.
Tangible Impact.

For over two decades, we have partnered with leading pharmaceutical companies to design cutting-edge experiments, uncover novel insights, and advance groundbreaking therapies.

Our research drives innovation, shaping the future of medicine through top-tier publications and global conference presentations.

lab_beaker_edited_edited_edited.jpg

Innovative Research.
Tangible Impact.

For over two decades, we have partnered with leading healthcare, biotech, and pharmaceutical companies to design cutting-edge experiments, uncover novel insights, and advance groundbreaking therapies.

Our research drives innovation, shaping the future of medicine through top-tier publications and global conference presentations.

completely white flat background light no other colors.jpg

2025 Feb 19

Cardiovascular Outcomes with Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial

​

Journal of the American Heart Association

14(5):e038656

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2025 Feb 13

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED a randomised trial

​

The Lancet Diabetes & Endocrinology

S2213-8587(24)00362-0

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2024 Oct 23

“A Time to Tear Down and a Time to Mend” – The Role of Eicosanoids in Atherosclerosis

​

Arteriosclerosis, Thrombosis, and Vascular Biology

44(11):2258-2263

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2024 Nov 11

REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees?

​

European Journal of Preventive Cardiology

31(15):e113-e114

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2024 Jun 3

Omega-3 fatty acids for Cardiovascular Event Lowering

​

European Journal of Preventive Cardiology

31(8):1005-1014

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2024 Jul 16

Eicosapentaenoic acid improves endothelial nitric oxide bioavailability via changes in protein expression during inflammation

​

Journal of the American Heart Association

13(14):e034076

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2024 Feb 17

Do patients benefit from omega-3 fatty acids?

​

Cardiovascular Research

119(18):2884-2901

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2024 Apr 23

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction with Icosapent Ethyl

​

Journal of the American College of Cardiology

83 (16):1529-1539

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2023 Nov 23

Omega-3 Fatty Acids Influence Membrane Cholesterol Distribution and Crystal Formation in Models of Atherosclerosis

​

Cholesterol Crystals in Atherosclerosis and Other Related Diseases

pp. 297-318

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2023 Nov 09

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

​

European Heart Journal

44:ehad6551309

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2023 Jun 2

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking.

​

European Heart Journal - Cardiovascular Pharmacotherapy

​

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2023 Apr 5

Eicosapentaenoic acid (EPA) reduces pulmonary endothelial dysfunction and inflammation due to changes in protein expression during exposure to particulate matter air pollution

​

Biomedicine & Pharmacotherapy

162:114629

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2023 Apr 4

Comparative Effects of Mineral Oil, Corn Oil, Eicosapentaenoic Acid, and Docosahexaenoic Acid in an In Vitro Atherosclerosis Model

​

Journal of the American Heart Association

12(7):e029109

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2022 Nov 15

Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy"

​

Circulation

146(20):e282-e283

Article

VIEW

completely white flat background light no other colors_edited.jpg
completely white flat background light no other colors.jpg

2022 May 21

A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes

​

Prostaglandins, Leukotrienes and Essential Fatty Acids

182:102450

Article

VIEW

completely white flat background light no other colors_edited.jpg
002-mTORCv5a-min_edited.jpg

Our partners

Scientific animation studio collaborating with pharmaceutical, biotech, and healthcare clients to produce highly-accurate and compelling custom 3D and 2D scientific visuals.

ELUCIDA EDUCATION

Our library of proprietary illustrations, figures, animations, interactive displays, posters, infographics, and supplementary materials for educational organizations.

UNDER DEVELOPMENT

COMPANY

Elucida's History

2001

Founded in

24

Years of Discoveries

20+

Partners and Clients Worldwide

500+

Publications in High-IF Journals

View our work

Our services provide value through two primary mechanisms:
 

  1. Data Generation – Our experiments deliver critical scientific insights into novel products, helping to direct their development, build scientific support, or highlight opportunities for differentiation from existing treatments.
     

  2. ​Scientific Support – By publishing our findings in top-tier journals, we enhance the visibility of your product or therapeutic, educating the scientific community and reinforcing its scientific foundation.

PAST CLIENTS

Connections in Healthcare & Biotech

bottom of page